Value through InnovationApril 18 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

Volasertib, Boehringer Ingelheim’s Investigational Oncology Compound, is Granted Orphan Drug Designation for Acute Myeloid Leukemia in the U.S. and EU

- For U.S. Media Only

Boehringer Ingelheim Reports 2013 Fiscal Year Results


Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin

- For U.S. Media Only

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism


Nearly 80 Percent of Cardiologists Say Ischemic Stroke Risk Reduction is Their Primary Goal in Non-valvular Atrial Fibrillation Treatment, New Survey Shows


New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)


CHMP Recommends Empagliflozin for Approval to Reduce Blood Sugar Levels in Adults with Type 2 Diabetes in Europe

- For U.S. Media

Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir

- For U.S. Media Only

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

- For U.S. Media

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma Severities

- For U.S. Media Only
back 1 2 3 4 5 6 7 8 9 10